Subscribe to RSS
DOI: 10.1055/s-2003-36335
Therapie der Arteriosklerose
Treatment of arteriosclerosisPublication History
eingereicht: 26.6.2002
akzeptiert: 20.8.2002
Publication Date:
02 January 2003 (online)

Summary
Arteriosclerotic disease develops over the course of several decades. Currently, a number of therapies are at hand to effectively stop this process and avoid complications of arteriosclerosis. Among the non-pharmacologic options, a balanced diet and physical activity predominate. A modern dietary plan offers a variety of tasty servings rich in fresh fruit and vegetables, cereals, fish, and poly-unsaturated fatty acids. The value of regular physical activity is demonstrated by the finding that an increase in exercise capacity („cardiorespiratory fitness”) by only one metabolic equivalent already reduces cardiovascular risk by 20-25 %. Regarding pharmacologic therapy, convincing data are available for cholesterol synthase inhibitors („statins”), some substances which influence the renin-angiotensin system (such as ramipril), and platelet aggregation inhibitors. Statins produce a 20 to 30 % reduction of cardiac death, myocardial infarction, and stroke. In patients with increased cardiovascular risk, the beneficial action of statins is also evident in subjects with low baseline cholesterol values. Apart from the cholesterol-lowering effects, anti-inflammatory and other vasoprotective mechanisms are involved. The angiotensin-converting enzyme inhibitor ramipril has demonstrated that even independent of blood-pressure lowering, cardiovascular events (cardiac death, myocardial infarction, stroke) are substantially reduced in high-risk patients. The effect is in the same order as that of statins. In patients with left-ventricular hypertrophy, the angiotensin-receptor antagonist losartan produces a notable reduction in stroke, independent of its blood-pressure lowering action. Finally, the platelet aggregation inhibitors aspirin and clopidogrel have proven benefit in secondary prevention and, in the case of aspirin, also in primary prevention in cardiovascular high-risk patients. The anti-arteriosclerotic properties of other substances are actively investigated, including calcium channel blockers, betablockers, and novel drug classes. From the medical point of view, a broader use of the well-proven and effective therapies of arteriosclerosis and its complications is clearly warranted.
Literatur
- 1
Albert C H, Campos H, Stampfer M J. et al .
Blood levels of
long-chain n-3 fatty acids and the risk of sudden death.
N
Engl J Med.
2002;
346
1113-1118
MissingFormLabel
- 2
Anand S S, Yusuf S.
Oral anticoagulant therapy
in patients with coronary artery disease: a meta-analysis.
JAMA.
1999;
282
2058-2067
MissingFormLabel
- 3
Anonymus. Gruppo
Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico .
Dietary
supplementation with n-3 polyunsaturated fatty acids and vitamin
E after myocardial infarction: results of the GISSI-Prevenzione trial.
Lancet.
1999;
354
447-455
MissingFormLabel
- 4
Antiplatelet Trialists’ Collaboration .
Collaborative
overview of randomised trials of antiplatelet therapy-I: Prevention
of death, myocardial infarction, and stroke by prolonged antiplatelet
therapy in various categories of patients.
BMJ.
1994;
308
81-106
MissingFormLabel
- 5
Blair S N, Kampert J B, Kohl H W 3rd. et al .
Influences of cardiorespiratory
fitness and other precursors on cardiovascular disease and all-cause
mortality in men and women.
JAMA.
1996;
276
205-210
MissingFormLabel
- 6
Brown B G, Zhao X Q, Chait A. et al .
Simvastatin and niacin, antioxidant vitamins,
or the combination for the prevention of coronary disease.
N
Engl J Med.
2001;
345
1583-1592
MissingFormLabel
- 7
CAPRIE Steering Committee .
A
randomised, blinded, trial of clopidogrel versus aspirin in patients
at risk of ischaemic events (CAPRIE).
Lancet.
1996;
348
1329-1339
MissingFormLabel
- 8
Chen Z, Peto R, Collins R. et
al .
Serum cholesterol concentration and coronary heart
disease in population with low cholesterol concentrations.
Br
Med J.
1991;
303
276-282
MissingFormLabel
- 9
Cullen P, Assmann G.
Primäre und sekundäre
Prävention der koronaren Herzkrankheit. Ein Positionspapier
der International Task Force for Prevention of Coronary Heart Disease.
Dtsch
Med Wochenschr.
2000;
125
881-87
MissingFormLabel
- 10
Dahlöf B, Devereux R B, Kjeldsen S E. et al. The LIFE Study Group .
Cardiovascular
morbidity and mortality in the Losartan Intervention For Endpoint
reduction in hypertension study (LIFE): a randomised trial against
atenolol.
Lancet.
2002;
359
995-1003
MissingFormLabel
- 11
de Lorgeril M, Salen P, Martin J L, Monjaud I, Delaye J, Mamelle N.
Mediterranean diet,
traditional risk factors, and the rate of cardiovascular complications
after myocardial infarction: final report of the Lyon Diet Heart
Study.
Circulation.
1999;
99
779-785
MissingFormLabel
- 12
Downs J R, Clearfield M, Weis S. et al .
Primary prevention of acute coronary events
with lovastatin in men and women with average cholesterol levels: results
of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis
Prevention Study.
JAMA.
1998;
279
1615-1622
MissingFormLabel
- 13
Fairfield K M, Fletcher R H.
Vitamins
for chronic disease prevention in adults.
JAMA.
2002;
287
3116-3126
MissingFormLabel
- 14
Frick M H, Elo O, Haapa K, Heinonen O P. et al .
Helsinki
Heart Study: primary-prevention trial with gemfibrozil in middle-aged
men with dyslipidemia. Safety of treatment, changes in risk factors,
and incidence of coronary heart disease.
N Engl J Med.
1987;
317
1237-1245
MissingFormLabel
- 15
Gaspoz J M, Coxson P G, Goldman P A. et al .
Cost effectiveness of aspirin,
clopidogrel, or both for secondary prevention of coronary heart
disease.
N Engl J Med.
2002;
346
1800-1806
MissingFormLabel
- 16
Gotto A M, Whitney E, Stein E A. et al .
Relation between
baseline and on-treatment lipid parameters and first acute major
coronary events in the Air Force/Texas Coronary Atherosclerosis
Prevention Study (AFCAPS/TexCAPS).
Circulation.
2000;
101
477-484
MissingFormLabel
- 17
Gotto A M, Farmer J A.
Pleiotropic
effects of statins: do they matter?.
Curr Opin Lipidol.
2001;
12
391-394
MissingFormLabel
- 18
Hambrecht R, Wolf A, Gielen S. et
al .
Effect of exercise on coronary endothelial function
in patients with coronary artery disease.
N Engl J Med.
2000;
342
454-460
MissingFormLabel
- 19
Heart Protection Study Collaborative
Group .
MRC/BHF Heart Protection Study of cholesterol
lowering with simvastatin in 20 536 high-risk individuals: a randomised
placebo-controlled trial.
Lancet.
2002;
360
7-22
MissingFormLabel
- 20
Heart Outcomes Prevention
Evaluation Study Investigators .
Vitamin E Supplementation
and Cardiovascular Events in High-Risk Patients.
N Engl
J Med.
2000;
342
154-160
MissingFormLabel
- 21
Hedblad B, Wikstrand J, Janzon L. et
al .
Low-dose metoprolol CR/XL and fluvastatin slow
progression of carotid intima-media thickness: Main results from
the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).
Circulation.
2001;
103
1721-1726
MissingFormLabel
- 22
Hulley S, Grady D, Bush T. et
al .
Randomized trial of estrogen plus progestin for
secondary prevention of coronary heart disease in postmenopausal
women. Heart and Estrogen/progestin Replacement Study (HERS)
Research Group.
JAMA.
1998;
280
605-613
MissingFormLabel
- 23
Krauss R M, Eckel R H, Howard B. et al .
AHA Dietary Guidelines: revision 2000:
A statement for healthcare professionals from the Nutrition Committee
of the American Heart Association.
Circulation.
2000;
102
2284-2299
MissingFormLabel
- 24
Lauer M S.
Clinical
practice. Aspirin for primary prevention of coronary events.
N
Engl J Med.
2002;
346
1468-1474
MissingFormLabel
- 25
Lee C D, Blair S N, Jackson A S.
Cardiorespiratory fitness, body composition, and
all-cause and cardiovascular disease mortality in men.
Am
J Clin Nutr.
1999;
69
373-380
MissingFormLabel
- 26
Long-Term Intervention with
Pravastatin in Ischaemic Disease (LIPID) Study Group .
Prevention
of cardiovascular events and death with pravastatin in patients
with coronary heart disease and a broad range of initial cholesterol
levels.
N Engl J Med.
1998;
339
1349-1357
MissingFormLabel
- 27
Lonn E, Yusuf S, Dzavik V. et
al .
SECURE Investigators. Effects of ramipril and vitamin
E on atherosclerosis: the study to evaluate carotid ultrasound changes
in patients treated with ramipril and vitamin E (SECURE).
Circulation.
2001;
103
919-95
MissingFormLabel
- 28
Malik I S, Bhatia V K, Kooner J S.
Cost effectiveness of ramipril treatment
for cardiovascular risk reduction.
Heart.
2001;
85
539-543
MissingFormLabel
- 29
Münzel T, Keaney J F.
Are
ACE inhibitors a „magic bullet” against oxidative
stress?.
Circulation.
2001;
104
1571-1574
MissingFormLabel
- 30
Myers J, Prakash M, Froelicher V. et
al .
Exercise capacity and mortality among men referred for
exercise testing.
N Engl J Med.
2002;
346
793-801
MissingFormLabel
- 31
National Cholesterol Education
Program Expert Panel on Detection, Evaluation and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III).
JAMA.
2001;
285
2486-2497
MissingFormLabel
- 32
Newby L K, Kristinsson A, Bhapkar M V. et al .
Early statin initiation
and outcomes in patients with acute coronary syndromes.
JAMA.
2002;
287
3087-3095
MissingFormLabel
- 33
Niebauer J, Hambrecht R, Velich T. et al .
Attenuated progression of coronary artery
disease after 6 years of multifactorial risk intervention: role
of physical exercise.
Circulation.
1997;
96
2534-2541
MissingFormLabel
- 34
Pedersen T R, Kjeshus J, Berg K. et al .
Randomised trial of cholesterol lowering
in 4444 patients with coronary heart disease: the Scandinavian Simvastatin
Survival Study (4S).
Lancet.
1994;
344
1383-1389
MissingFormLabel
- 35
Pitt B, Waters D, Brown W V. et al .
Aggressive lipid-lowering therapy compared
with angioplasty in stable coronary artery disease. Atorvastatin
versus Revascularization Treatment Investigators.
N Engl
J Med.
1999;
341
70-76
MissingFormLabel
- 36
PROGRESS Collaborative Group .
Randomised
trial of a perindopril-based blood-pressure-lowering regimen among
6,105 individuals with previous stroke or transient ischaemic attack.
Lancet.
2001;
358
1033-1041
MissingFormLabel
- 37
Ridker P M, Rifai N, Clearfield M. et al .
Measurement of C-reactive protein for the
targeting of statin therapy in the primary prevention of acute coronary events.
N
Engl J Med.
2001;
344
1959-1965
MissingFormLabel
- 38
Rimm E B, Stampfer M J.
Wine, beer,
and spirits - are they really horses of a different color?.
Circulation.
2002;
105
2806-2807
MissingFormLabel
- 39
Roger V L, Jacobsen S J, Pellikka P A. et al .
Prognostic value of treadmill
exercise testing. A population-based study in Olmsted County, Minnesota.
Circulation.
1998;
98
2836-2841
MissingFormLabel
- 40
Rubins H B, Robins S J, Collins D. et al .
Gemfibrozil for the secondary prevention
of coronary heart disease in men with low levels of high-density
lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein
Cholesterol Intervention Trial Study Group.
N Engl J Med.
1999;
341
410-418
MissingFormLabel
- 41
Sacks F M, Pfeffer M A, Moye L A. et al .
The effect of pravastatin
on coronary events after myocardial infarction in patients with
average cholesterol levels: Cholesterol and Recurrent Events Trial
investigators.
N Engl J Med.
1996;
335
1001-1009
MissingFormLabel
- 42
Schartl M, Bocksch W, Koschyk D H. et al .
Use of intravascular ultrasound to compare
effects of different strategies of lipid-lowering therapy on plaque volume
and composition in patients with coronary artery disease.
Circulation.
2001;
104
387-392
MissingFormLabel
- 43
Schwartz G G, Olsson A G, Ezekowitz M D. et al. for the Myocardial Ischemia Reduction
with Aggressive Cholesterol Lowering (MIRACL) Study Investigators .
Effects
of atorvastatin on early recurrent ischemic events in acute coronary
syndromes: the MIRACL study: a randomized controlled trial.
JAMA.
2001;
285
1711-1718
MissingFormLabel
- 44
Serruys P W, de Feyter P, Macaya C. et al. Lescol Intervention Prevention Study (LIPS) Investigators .
Fluvastatin
for prevention of cardiac events following successful first percutaneous
coronary intervention: a randomized controlled trial.
JAMA.
2002;
287
3215-3222
MissingFormLabel
- 45
Shepherd J, Cobbe S M, Ford I. et al, for the West of Scotland Coronary Prevention Study Group .
Prevention
of coronary artery disease with pravastatin in men with hypercholesterolemia.
New
Engl J Med.
1995;
333
1301-07
MissingFormLabel
- 46
Smith S C, Blair S N, Bonow R O. et al .
AHA/ACC
Scientific Statement: AHA/ACC guidelines for preventing
heart attack and death in patients with atherosclerotic cardiovascular
disease: 2001 update: A statement for healthcare professionals from
the American Heart Association and the American College of Cardiology.
Circulation.
2001;
104
1577-1579
MissingFormLabel
- 47
Stofan J R, DiPietro L, Davis D. et
al .
Physical activity patterns associated with cardiorespiratory
fitness and reduced mortality: the Aerobics Center Longitudinal
Study.
Am J Public Health.
1998;
88
1807-1813
MissingFormLabel
- 48
van Hout B A, Simoons M L.
Cost-effectiveness
of HMG coenzyme reductase inhibitors; whom to treat?.
Eur
Heart J.
2001;
22
751-761
MissingFormLabel
- 49
Williams J K, Sukhova G K, Herrington D M, Libby P.
Pravastatin
has cholesterol-lowering independent effects on the artery wall
of atherosclerotic monkeys.
J Am Coll Cardiol.
1998;
31
684-691
MissingFormLabel
- 50
Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K.
Prevention
of coronary heart disease in clinical practice. Recommendations
of the Second Joint Task Force of European and other Societies on
Coronary Prevention.
Eur Heart J.
1998;
19
1434-1503
MissingFormLabel
- 51
Writing Group for the Women’s
Health Initiative Investigators .
Risks and benefits
of estrogen plus progestin in healthy postmenopausal women. Principal
results from the Women’s Health Initiative randomized controlled
trial.
JAMA.
2002;
288
321-333
MissingFormLabel
- 52
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.
Effects of an angiotensin-converting-enzyme
inhibitor, ramipril, on cardiovascular events in high-risk patients.
The Heart Outcomes Prevention Evaluation Study Investigators.
N
Engl J Med.
2000;
342
145-213
MissingFormLabel
Dr. med. Axel Schmermund
Abteilung für Kardiologie, Universitätsklinikum
Essen
Hufelandstraße 55
45122 Essen
Phone: 0201/7232339
Fax: 0201/7234405
Email: Axel.Schmermund@uni-essen.de